CD274 and neoplasm: In the phase III EAGLE trial, data from the durvalumab monotherapy arm demonstrated a median OS of 9.8 months in patients with tumor PD-L1 expression ≥25%, compared with 7.6 months in patients with tumor PD-L1 expression <25% (18).